VERTEX PHARMACEUTICALS INC (VRTX) Stock Analyst Ratings
NASDAQ:VRTX • US92532F1003
470.31 USD
-7.01 (-1.47%)
At close: Feb 18, 2026
472.709 USD
+2.4 (+0.51%)
After Hours: 2/18/2026, 8:06:45 PM
ChartMill assigns a Buy % Consensus number of 80% to VRTX. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 532.5. This target is 13.22% above the current price.
- VRTX was analyzed by 39 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about VRTX.
- In the previous month the buy percentage consensus was at a similar level.
- VRTX was analyzed by 39 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-17 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-17 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2026-02-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-13 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2026-02-13 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2026-02-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-13 | Stifel | Maintains | Hold -> Hold |
| 2026-02-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-28 | Barclays | Upgrade | Equal-Weight -> Overweight |
| 2026-01-26 | UBS | Maintains | Buy -> Buy |
| 2026-01-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-22 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2026-01-12 | Bernstein | Upgrade | Market Perform -> Outperform |
| 2026-01-06 | Wolfe Research | Upgrade | Peer Perform -> Outperform |
| 2025-12-29 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-03 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-11-07 | UBS | Maintains | Buy -> Buy |
| 2025-11-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-11-04 | Stifel | Maintains | Hold -> Hold |
| 2025-11-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-08 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-25 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-09-11 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-03 | Raymond James | Initiate | Market Perform |
| 2025-08-06 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-06 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
VERTEX PHARMACEUTICALS INC / VRTX FAQ
Can you provide the average price target for VERTEX PHARMACEUTICALS INC stock?
39 analysts have analysed VRTX and the average price target is 532.5 USD. This implies a price increase of 13.22% is expected in the next year compared to the current price of 470.31.
What is the consensus rating for VRTX stock?
The consensus rating for VERTEX PHARMACEUTICALS INC (VRTX) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover VERTEX PHARMACEUTICALS INC (VRTX) stock?
The number of analysts covering VERTEX PHARMACEUTICALS INC (VRTX) is 39.